VQW-765
Phase 3Small molecule
VQW-765 is one of 71 small molecule programs targeting Anxiety. It is currently in Phase 3.
3
Indications
2
Total Trials
1
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
165 competitors in Anxiety
#DrugCompanyPhaseTrials
1Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Duragesic
CCephalon
Phase 3
Duloxetine Hydrochloride
Eli LillyPhase 3
Centanafadine
OtsukaPhase 3
VQW-765
VVanda Pharmaceuticals
Phase 3
Yohimbine Hydrochloride
UUnknown Sponsor
Phase 3
Celexa
AbbViePreclinical
Spravato
WWim Janssens
Preclinical
Campral
FForest Laboratories
Preclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VQW-765. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVanda Pharmaceuticals